clinical trial · NCT05127304
A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
Boehringer Ingelheim·—·completed·n = 11,316
Pulmonary Disease, Chronic ObstructiveTrelegy ElliptaStiolto RespimatFuroate/Umeclidinium/VilanterolTiotropium Bromide/Olodaterol
brief summary
The purpose of this study is to estimate disease-related and all-cause burden and clinical outcomes of interest following initiation of chronic obstructive lung disease (COPD) maintenance therapy with Tiotropium Bromide/Olodaterol (TIO/OLO) or Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
started
Feb 26, 2021
primary completion
Feb 3, 2022
completion
Feb 3, 2022
last updated
Nov 13, 2023
official title
Health Care Resource Utilization, Cost and Other Outcomes of Patients Diagnosed With COPD Initiating Tiotropium Bromide/Olodaterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol